Cargando…
Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) has relatively ineffective first/second-line therapy for advanced disease and only 18% five-year survival for early disease. Drug-induced mitochondrial priming measured by dynamic BH3 profiling identifies efficacious drugs in multiple disease settings. We use hig...
Autores principales: | Potter, Danielle S., Du, Ruochen, Bohl, Stephan R., Chow, Kin-Hoe, Ligon, Keith L., Bueno, Raphael, Letai, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199949/ https://www.ncbi.nlm.nih.gov/pubmed/37210412 http://dx.doi.org/10.1038/s41467-023-38552-z |
Ejemplares similares
-
Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer
por: Potter, Danielle S., et al.
Publicado: (2021) -
Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
por: Wadowski, Benjamin, et al.
Publicado: (2021) -
Cytomegalovirus infection in malignant pleural mesothelioma
por: Hunter-Schlichting, DeVon, et al.
Publicado: (2021) -
Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma
por: Gill, Ritu R, et al.
Publicado: (2017) -
Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)